The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Cannabis in Rheumatology Care: A Look at the Latest Research & What Rheumatologists Are Telling Their Patients

Cannabis in Rheumatology Care: A Look at the Latest Research & What Rheumatologists Are Telling Their Patients

March 26, 2018 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Even in states where marijuana isn’t legal to purchase, such as Georgia, patients ask regularly about how marijuana and cannabis oil may be included in their treatment, says Kelly Weselman, MD, FACR, a rheumatologist with the WellStar Health System in Atlanta. “It’s difficult to have to tell patients we just don’t know,” she says.

You Might Also Like
  • Medical Cannabis Helps Chronic Pain Patients Cut Opioid Use
  • Medical Marijuana Use by Rheumatology Patients Needs Closer Look
  • Little Evidence Shows Cannabis Helps Chronic Pain or PTSD
Explore This Issue
April 2018
Also By This Author
  • All in One Setting: Integrated Team-Based Care for Autoimmunity

Evolving Research, Legalization
The research exploring medicinal cannabis in various forms for rheumatology is “evolving very rapidly,” says Daniel Clauw, MD, a professor of anesthesiology, medicine (rheumatology) and psychiatry and director of the Chronic Pain and Fatigue Research Center at the University of Michigan in Ann Arbor.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

He notes one of the most exciting studies in this area was recently completed by a pharmaceutical company for which he serves as a scientific advisory board member. During the study, researchers showed that CBD alone seems to be effective for treating osteoarthritis.

“This [finding] is exciting because CBD has very few side effects compared with THC,” he shares. “Also, many research studies with cannabis are suggesting that low doses may be more effective than high doses.” Dr. Clauw has also been involved in research exploring cannabis as a more effective option for pain relief than opioids.3,4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Regardless of trends toward legalization at the state level, marijuana is still considered a Schedule 1 drug by the U.S. federal government, a status that remains a significant barrier to research. However, Dr. Clauw suggests rheumatologists in the U.S. pay close attention to good quality studies on cannabis coming from colleagues outside of the U.S., including those working in Canada, Australia and Europe.

In Canada, Mary-Ann Fitzcharles, MD, an associate professor of medicine in the Division of Rheumatology and the Alan Edwards Pain Management Unit at McGill University in Montreal, has long explored the benefits and risks of medicinal cannabis, including its synthetic forms, for pain management.5

With the rapidly increasing legalization of marijuana, Dr. Fitzcharles believes focused clinical research is more critical than ever. In July 2018, marijuana will become a legal recreational substance throughout Canada and is currently available in the country for medicinal use by prescription. She says medical marijuana is available in varying concentrations of THC and CBD. But some concentrations of THC are as high as 30%, which is unacceptable from a medical standpoint. This very high THC content can only be explained as a means to meet the demands for an underlying recreational use being justified as a medicinal therapy, she says. She notes that THC content in recreational marijuana has progressively increased from around 3% in the 1970s to levels as high as 30% today.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Drug Updates Tagged With: cannabinoid, cannabis, Legal, marijuana, medical marijuanaIssue: April 2018

You Might Also Like:
  • Medical Cannabis Helps Chronic Pain Patients Cut Opioid Use
  • Medical Marijuana Use by Rheumatology Patients Needs Closer Look
  • Little Evidence Shows Cannabis Helps Chronic Pain or PTSD
  • Marijuana for Rheumatology Patients?

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)